These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 26708937)
21. The immune response in cancer: from immunology to pathology to immunotherapy. Giraldo NA; Becht E; Vano Y; Sautès-Fridman C; Fridman WH Virchows Arch; 2015 Aug; 467(2):127-35. PubMed ID: 26077464 [TBL] [Abstract][Full Text] [Related]
22. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Roelands J; Kuppen PJK; Vermeulen L; Maccalli C; Decock J; Wang E; Marincola FM; Bedognetti D; Hendrickx W Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064420 [TBL] [Abstract][Full Text] [Related]
23. Immune-based identification of cancer patients at high risk of progression. Vano YA; Petitprez F; Giraldo NA; Fridman WH; Sautès-Fridman C Curr Opin Immunol; 2018 Apr; 51():97-102. PubMed ID: 29554496 [TBL] [Abstract][Full Text] [Related]
24. Exosomes Function in Tumor Immune Microenvironment. Huang Y; Liu K; Li Q; Yao Y; Wang Y Adv Exp Med Biol; 2018; 1056():109-122. PubMed ID: 29754177 [TBL] [Abstract][Full Text] [Related]
25. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Camisaschi C; Vallacchi V; Castelli C; Rivoltini L; Rodolfo M Expert Rev Mol Diagn; 2014 Jul; 14(6):643-6. PubMed ID: 24914691 [TBL] [Abstract][Full Text] [Related]
27. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018 [TBL] [Abstract][Full Text] [Related]
28. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511 [TBL] [Abstract][Full Text] [Related]
29. Metabolic Barriers to T Cell Function in Tumors. Sugiura A; Rathmell JC J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381 [TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Gajewski TF; Woo SR; Zha Y; Spaapen R; Zheng Y; Corrales L; Spranger S Curr Opin Immunol; 2013 Apr; 25(2):268-76. PubMed ID: 23579075 [TBL] [Abstract][Full Text] [Related]
31. Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications. Di Caro G; Castino GF; Bergomas F; Cortese N; Chiriva-Internati M; Grizzi F; Mantovani A; Marchesi F Int Rev Immunol; 2015 Mar; 34(2):123-33. PubMed ID: 25901857 [TBL] [Abstract][Full Text] [Related]
32. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Gajewski TF Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069 [TBL] [Abstract][Full Text] [Related]
33. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Sasada T; Suekane S Immunotherapy; 2011 Oct; 3(10):1235-51. PubMed ID: 21995574 [TBL] [Abstract][Full Text] [Related]
35. Computational deconvolution of transcriptomic data for the study of tumor-infiltrating immune cells. Bolis M; Vallerga A; Fratelli M Int J Biol Markers; 2020 Feb; 35(1_suppl):20-22. PubMed ID: 32079462 [TBL] [Abstract][Full Text] [Related]
37. The clinical role of the TME in solid cancer. Giraldo NA; Sanchez-Salas R; Peske JD; Vano Y; Becht E; Petitprez F; Validire P; Ingels A; Cathelineau X; Fridman WH; Sautès-Fridman C Br J Cancer; 2019 Jan; 120(1):45-53. PubMed ID: 30413828 [TBL] [Abstract][Full Text] [Related]
38. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nagarsheth N; Wicha MS; Zou W Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670 [TBL] [Abstract][Full Text] [Related]
39. Disentangling the relationship between tumor genetic programs and immune responsiveness. Bedognetti D; Hendrickx W; Ceccarelli M; Miller LD; Seliger B Curr Opin Immunol; 2016 Apr; 39():150-8. PubMed ID: 26967649 [TBL] [Abstract][Full Text] [Related]